Company news

AnaptysBio, Inc. news in 2026

AnaptysBio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

October 19, 2026

Annual Transition Report (Form 10-KT)

September 21, 2026

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

September 1, 2026

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

May 11, 2026

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

April 24, 2026

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

April 20, 2026

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

March 26, 2026

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

March 26, 2026

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

March 26, 2026

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

March 3, 2026

Anaptys Announces Participation at Upcoming Investor Conferences

February 5, 2026

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

January 8, 2026

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026